Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide
2. 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
3. 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4. E 7080
5. E-7080
6. E-7080 Mesylate
7. E7080
8. E7080 Mesylate
9. Er-203492-00
10. Lenvatinib
11. Lenvatinib Mesilate
12. Lenvatinib Metabolite M2
13. Lenvatinib Methanesulfonate
14. Lenvima
15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate
1. 857890-39-2
2. Lenvima
3. Lenvatinibmesylate
4. Lenvatinib Mesilate
5. Lenvatinib Mesylate [usan]
6. E7080 Mesylate
7. Lenvatinib (mesylate)
8. Unii-3j78384f61
9. E-7080 Mesylate
10. Chebi:85995
11. 857890-39-2 (mesylate)
12. 3j78384f61
13. Lenvatinib Mesilate (jan)
14. Lenvatinib Mesylate (usan)
15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate
16. Lenvatinib Mesilate [jan]
17. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Mesylate
18. 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;methanesulfonic Acid
19. 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide Monomethanesulfonate
20. Lenvima (tn)
21. E7080mesylate
22. E7080 (mesylate)
23. Lenvatinib Methanesulfonate
24. Lenvatinib Mesylate- Bio-x
25. Schembl865174
26. Amy385
27. Chembl2105704
28. Dtxsid90235081
29. Bcp11858
30. Hy-10981a
31. Lenvatinib Mesilate [who-dd]
32. Mfcd18633219
33. Ccg-269873
34. Sb16581
35. Lenvatinib Methanesulfonate [mi]
36. Lenvatinib Mesylate [orange Book]
37. Ac-30100
38. Bl166696
39. Ds-19245
40. Cs-0030963
41. S5240
42. D09920
43. A900902
44. Q27158839
45. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Methanesulfonate
46. 6-carbamoyl-4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinolin-1-ium Methanesulfonate
47. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-, Methanesulfonate (1:1)
48. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-, Methanesulfonate (1:1)
49. Methanesulfonic Acid--4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide (1/1)
Molecular Weight | 523.0 g/mol |
---|---|
Molecular Formula | C22H23ClN4O7S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 522.0975980 g/mol |
Monoisotopic Mass | 522.0975980 g/mol |
Topological Polar Surface Area | 178 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 727 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-10-24
Pay. Date : 2018-08-09
DMF Number : 32905
Submission : 2018-06-26
Status : Active
Type : II
Date of Issue : 2022-05-26
Valid Till : 2025-07-07
Written Confirmation Number : WC-0039n
Address of the Firm :
NDC Package Code : 71796-005
Start Marketing Date : 2018-06-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2024-10-25
Registration Number : No. 574-26-ND
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : CTO Unit-VI, APIIC Industrial Estate, Pydibhimavaram Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh - 532 409, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-11-30
Pay. Date : 2021-11-08
DMF Number : 36031
Submission : 2021-06-30
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41489
Submission : 2025-03-24
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-27
Pay. Date : 2018-12-12
DMF Number : 33331
Submission : 2019-02-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33964
Submission : 2019-06-27
Status : Active
Type : II
NDC Package Code : 17337-0314
Start Marketing Date : 2022-05-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-11-26
Pay. Date : 2024-09-30
DMF Number : 37347
Submission : 2022-07-28
Status : Active
Type : II
NDC Package Code : 17337-0099
Start Marketing Date : 2021-10-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-11-20
Pay. Date : 2018-09-04
DMF Number : 33083
Submission : 2018-09-04
Status : Active
Type : II
NDC Package Code : 82920-036
Start Marketing Date : 2022-08-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-25
Pay. Date : 2018-11-19
DMF Number : 33017
Submission : 2018-08-07
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm :
NDC Package Code : 54893-0112
Start Marketing Date : 2021-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2025-02-10
Registration Number : No. 674-4-ND(A)
Manufacturer Name : MSN Laboratories Private Limited
Manufacturer Address : Unit-II, Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Telangana, Pincode: 502 300, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2021-11-30
Pay. Date : 2021-11-08
DMF Number : 36031
Submission : 2021-06-30
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2018-10-24
Pay. Date : 2018-08-09
DMF Number : 32905
Submission : 2018-06-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-01-24
Pay. Date : 2021-12-16
DMF Number : 36197
Submission : 2021-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39887
Submission : 2024-04-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-31
Pay. Date : 2023-03-17
DMF Number : 35779
Submission : 2021-03-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-03-25
Pay. Date : 2018-11-19
DMF Number : 33017
Submission : 2018-08-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33964
Submission : 2019-06-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-11-26
Pay. Date : 2024-09-30
DMF Number : 37347
Submission : 2022-07-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-20
Pay. Date : 2018-09-04
DMF Number : 33083
Submission : 2018-09-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41489
Submission : 2025-03-24
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm : Chemical Technical Operations Unit-VI, APIIC Industrial Estate, Pydibhimavaram V...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-05-26
Valid Till : 2025-07-07
Written Confirmation Number : WC-0039n
Address of the Firm : Unit-l, Plot Nos., 137,138,145 & 146, Sri Venkateswara Cooperative Industrial Es...
Lenvatinib Mesylate DMSO Solvate IH
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
Lenvatinib mesilate DMSO Solvate IH
Date of Issue : 2019-10-07
Valid Till : 2022-05-05
Written Confirmation Number : WC-0349A5-A6
Address of the Firm : Unit-||, Sy. No. 50, Kardanur Village, Patti/Post Patancheru Mandal,Sangareddy D...
Date of Issue : 2019-10-07
Valid Till : 2022-06-12
Written Confirmation Number : WC-0372
Address of the Firm : S. No. 73/1A, 74/7B, 78/1B, 79/1, 2B 3 4B 5 6A, 6B, 7, 80/1,2 3,4, 84/1, 2, 3A, ...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2024-10-25
Registration Number : No. 574-26-ND
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : CTO Unit-VI, APIIC Industrial Estate, Pydibhimavaram Village, Ranasthalam Mandal, Sri...
Registrant Name : Korea Ezai Co., Ltd.
Registration Date : 2015-10-07
Registration Number : No. 3834-5-ND
Manufacturer Name : Kashima Plant, Eisai Co., Lt...
Manufacturer Address : 22 Sunayama, Kamisu-shi, Ibaraki-ken 314-0255
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2025-02-10
Registration Number : No. 674-4-ND(A)
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Unit-II, Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sa...
Registrant Name : Grace Farm
Registration Date : 2023-08-07
Registration Number : No. 674-4-ND
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Unit-II, Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sa...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-005
Start Marketing Date : 2018-06-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0077
Start Marketing Date : 2018-08-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0112
Start Marketing Date : 2021-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0099
Start Marketing Date : 2021-10-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0314
Start Marketing Date : 2022-05-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82920-036
Start Marketing Date : 2022-08-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
About the Company : Sumar Biotech LLP, registered in January 2018, is a startup approved by the Gujarat State Biotechnology Mission. It was founded by emerging entrepreneurs and a team of young yet ex...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Established in 2010, Mac-Chem is a NMM Group company. Mac-Chem is focused on oncology and other niche specialty APIs. It supplies quality APIs to the top 15 oncology players in Ind...
About the Company : Parsian Pharmaceutical is dedicated to improving health outcomes by offering high-quality, effective pharmaceutical products. With a strong commitment to research, innovation, and ...
About the Company : Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November...
About the Company : Sichuan Qingmu Pharmaceutical Co., Ltd, is a FDA approved cGMP factory in China, focusing on APIs’ production. The products are mainly Oncology APIs, Cardiovascular APIs, and Vet...
About the Company : We are a world class innovation driven specialty pharmaceutical company with integrated Research, Development, Manufacturing and Marketing of Quality affordable medicines for a Hea...
Market Place
Reply
02 Dec 2022
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
75
PharmaCompass offers a list of Lenvatinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lenvatinib Mesylate manufacturer or Lenvatinib Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lenvatinib Mesylate manufacturer or Lenvatinib Mesylate supplier.
PharmaCompass also assists you with knowing the Lenvatinib Mesylate API Price utilized in the formulation of products. Lenvatinib Mesylate API Price is not always fixed or binding as the Lenvatinib Mesylate Price is obtained through a variety of data sources. The Lenvatinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lenvatinib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lenvatinib Mesylate, including repackagers and relabelers. The FDA regulates Lenvatinib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lenvatinib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lenvatinib Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lenvatinib Mesylate supplier is an individual or a company that provides Lenvatinib Mesylate active pharmaceutical ingredient (API) or Lenvatinib Mesylate finished formulations upon request. The Lenvatinib Mesylate suppliers may include Lenvatinib Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Lenvatinib Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lenvatinib Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Lenvatinib Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Lenvatinib Mesylate DMFs exist exist since differing nations have different regulations, such as Lenvatinib Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lenvatinib Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Lenvatinib Mesylate USDMF includes data on Lenvatinib Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lenvatinib Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lenvatinib Mesylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lenvatinib Mesylate Drug Master File in Korea (Lenvatinib Mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lenvatinib Mesylate. The MFDS reviews the Lenvatinib Mesylate KDMF as part of the drug registration process and uses the information provided in the Lenvatinib Mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lenvatinib Mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lenvatinib Mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lenvatinib Mesylate suppliers with KDMF on PharmaCompass.
A Lenvatinib Mesylate written confirmation (Lenvatinib Mesylate WC) is an official document issued by a regulatory agency to a Lenvatinib Mesylate manufacturer, verifying that the manufacturing facility of a Lenvatinib Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lenvatinib Mesylate APIs or Lenvatinib Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Lenvatinib Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Lenvatinib Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lenvatinib Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lenvatinib Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lenvatinib Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lenvatinib Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lenvatinib Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lenvatinib Mesylate suppliers with NDC on PharmaCompass.
Lenvatinib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lenvatinib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lenvatinib Mesylate GMP manufacturer or Lenvatinib Mesylate GMP API supplier for your needs.
A Lenvatinib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Lenvatinib Mesylate's compliance with Lenvatinib Mesylate specifications and serves as a tool for batch-level quality control.
Lenvatinib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Lenvatinib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lenvatinib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Lenvatinib Mesylate EP), Lenvatinib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lenvatinib Mesylate USP).